J&J invests $785M in Sail Biomedicines, secures option to buy for $2.58B

Johnson & Johnson has agreed to pay $785 million up front to Sail Biomedicines, including a $465 million equity infusion and up to $140 million in milestone payments. The agreement also gives J&J an exclusive right to acquire Sail later for an additional $2.58 billion.

The move comes as interest in in‑vivo CAR‑T cell therapies has surged, with several large pharma companies committing billions to the approach. Recent examples include AbbVie, AstraZeneca, Bristol Myers Squibb, Gilead’s Kite and Eli Lilly’s $3.25 billion deal for Kelonia Therapeutics.

Sail’s pipeline centers on its “vanguard” in‑vivo CAR‑T platform aimed at autoimmune diseases, led by candidate SAIL‑0839 that targets both CD4 and CD8 T cells. The company has highlighted the use of circular RNA to improve the stability and durability of its engineered cells.

By deepening its partnership with Sail, J&J is expanding its footprint in the cell‑and‑gene therapy space and positioning itself for a potential future acquisition if the program delivers promising results.